A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265). Conference Paper uri icon

authors

  • Long, Georgina V
  • Dummer, Reinhard
  • Ribas, Antoni
  • Puzanov, Igor
  • Michielin, Olivier
  • Vanderwalde, Ari M
  • Andtbacka, Robert Hans Ingemar
  • Cebon, Jonathan S
  • Fernandez, Eugenio
  • Malvehy, Josep
  • Olszanski, Anthony J
  • Gajewski, Thomas
  • Kirkwood, John M
  • Kuznetsova, Olga
  • Chen, Lisa
  • Diede, Scott J
  • Chou, Jeffrey
  • Hodi, F Stephen

publication date

  • May 20, 2016